Parkinsonism induced by high-dose cytosine arabinoside.
We report a severe parkinsonian condition following high dose, parenteral cytosine arabinoside (Cytosar) that persisted for 8 weeks. The drug was used in a patient with acute myelogenous leukemia that was refractory to all other treatment. The syndrome was partially responsive to antiparkinsonian drugs and fortunately remitted completely within 12 weeks.
D002230:Carbidopa / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy*; D007980:Levodopa / Q000008:administration & dosage; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy
D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D003561:Cytarabine; D007980:Levodopa; D002230:Carbidopa